Puma Biotech (PBYI) Tops Q3 EPS by 113c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Puma Biotech (PBYI) Tops Q3 EPS by 113c

Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'

November 10, 2017 1:10 PM EST

Barclays raised its price target on Puma Biotech (NASDAQ: PBYI) to $122.00 (from $103.00) while maintaining a Overweight rating, following the company's third quarter earnings report.

Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share and... More

Puma Biotechnology (PBYI) PT Raised to $142 at Credit Suisse, 'Early Trend Indicators Stronger Trajectory'

November 10, 2017 4:56 AM EST

Credit Suisse raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $142.00 (from $136.00) while maintaining a Outperform rating.

Analyst Alethia Young models Nerlynx Q4 and 2018 sales at $28 million and $214 million respectively. The analyst believes the selloff following Thursday's report was due to high... More

Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'

November 10, 2017 4:14 AM EST

Citi raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $164.00 (from $156.00) while maintaining a Buy rating.

Analyst Yigal Nochomovitz believes investors should buy the dip noting early metrics are looking very good even without the benefit of EAP and modest discontinuations. The... More